CN101412687B - 旋光纯富马酸伊布利特的制备方法 - Google Patents

旋光纯富马酸伊布利特的制备方法 Download PDF

Info

Publication number
CN101412687B
CN101412687B CN2008101221881A CN200810122188A CN101412687B CN 101412687 B CN101412687 B CN 101412687B CN 2008101221881 A CN2008101221881 A CN 2008101221881A CN 200810122188 A CN200810122188 A CN 200810122188A CN 101412687 B CN101412687 B CN 101412687B
Authority
CN
China
Prior art keywords
ethyl
heptyl
phenyl
optically
pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008101221881A
Other languages
English (en)
Other versions
CN101412687A (zh
Inventor
牧初春
李新生
徐东成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Normal University CJNU
Original Assignee
Zhejiang Normal University CJNU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Normal University CJNU filed Critical Zhejiang Normal University CJNU
Priority to CN2008101221881A priority Critical patent/CN101412687B/zh
Publication of CN101412687A publication Critical patent/CN101412687A/zh
Application granted granted Critical
Publication of CN101412687B publication Critical patent/CN101412687B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Abstract

旋光纯富马酸伊布利特的制备方法,其特征在于,用CBS催化剂对N-乙基-N-庚基-4-氧代-4-(4-甲磺酰氨基苯基)丁酰胺进行不对称催化还原,得到(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺,用LiAlH4对(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺进行还原,最后与富马酸成盐反应最终得到旋光纯富马酸伊布利特。该制备方法操作简便、反应条件温和、对映选择性好、环境友好、成本低,产率高。

Description

旋光纯富马酸伊布利特的制备方法
技术领域
本发明涉及旋光性药物合成领域,特别涉及旋光纯富马酸伊布利特的制备方法。 
背景技术
Figure DEST_PATH_G200810122188101D00011
   富马酸伊布利特           富马酸伊布利特(ibutilide fumarate),英文名:ibutilide fumarate,化学名:N-[4-[4-(Ethylheptylamino)-1-hydroxybutyl]phenyl]methanesulfonamide,(E)-2-Butenedioate(2:1)Salt,结构式见左式。是由美国普强公司研发的一种新型离子通道拮抗剂类抗心律失常药,1996年首次在美国上市,商品名Convert,另在德国等11个国家上市。临床用其注射液主要用于心房颤动和心房扑动的转复。富马酸伊布利特是新型III类抗心律失常药物,临床研究表明:该药疗效显著、具有高度选择性。平均终止心律不齐时间短,80%患者给药后在30分钟内可全面好转。对于急性发作有效性、安全性的全面评估表明,房扑转复成功率为48~70%,房颤为22~43%,优于索他洛尔和普鲁卡因酰胺转复成功率数倍,对心脏搭桥术后的房颤和房扑安全有效,心律转复率达57%。目前富马酸伊布利特以外消旋体作为治疗药物,外消旋体是由等量的对映体组成的物质,无旋光性。该药物虽然具有较好的疗效,但也具有一定的副作用,这很可能是消旋体化合物中一个对映体具有较强的副作用引起的。 
富马酸伊布利特具有一个手性碳原子,合成的关键在于如何得到手性仲醇。目前富马酸伊布利特合成方法有:Hester,J.B.;Gibson,J.K.;Cimini,M.G.;Emmert,D.E.;Locker,P.K.;Perricone,S.C.;Skaletzky,L.L.;Sykes,J.K.;West,B.E.N-[(ω-Amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.J.Med.Chem.,1991,34(1):308-315.中记载了以甲磺酰苯胺为起始原料,经傅克反应,缩合得到N-乙基-N-庚基-4-氧代-4-(4-甲磺酰氨基苯基)丁酰胺,再经还原和成盐反应首次合成富马酸伊布利特,总产率为17%左右;Perricone,S.C.;Chidester,C.G.;Hester,J.B.Synthesis of(R)-N-[4-[4-(Dibutylamino)-1-hydroxybutyl]phenyl]methanesulfonamide,(E)-2-Butene-dioate(2:1)Salt(Artilide Fumarate)and the Enantiomers of N-[4-[4-(Et-hylheptylamino)-1-hydroxybutyl]phenyl]methanesulfonamide,(E)-2-Butenedi-oate(2:1)Salt(Ibutilide Fumarate)[J].Tetrahedron:Asymmetry.,1996,7(3):677-690.中记载了Hester课题组通过用二蒎烷基氯化硼为还原剂对N-乙基-N-庚基-4-氧代-4-(4-甲磺酰氨基苯基)丁酰胺进行化学计量不对称还原(该步反应的产率为46.6%),再经还原和成盐反应首次得到旋光纯富马酸伊布利特。但该方法用二蒎烷基氯化硼为还原剂,其价格较贵,工业化成本太高。其他的合成方法都是消旋体富马酸伊布利特的合成,没有涉及到旋光纯富马酸伊布利特合成。 
旋光纯富马酸伊布利特是对映体中的一种:(S)-N-[4-[4-(乙基庚基氨基)-1-羟丁基]苯基]甲磺酰胺,(E)-2-丁烯二酸(2:1)或(R)-N-[4-[4-(乙基庚基氨基)-1-羟丁基]苯基]甲磺酰胺,(E)-2-丁烯二酸(2:1),具有旋光性。 
不对称合成目前认为最完整的表述是“底物分子中潜手性单元与反应物作用形成不等量立体异构体的过程”,该定义中的潜手性单元可以是含 有重键的平面基团如羰基。在不对称反应中,若底物经转换后形成不等量的一对对映异构体,则该反应称为对映选择反应。根据不对称因素来源,可将不对称反应分为:(1)手性底物控制;(2)手性辅助基团控制;(3)手性试剂控制和(4)手性催化剂控制。酮类化合物的不对称还原可以通过如下主要途径实现:(1)使用手性氢负离子还原剂;(2)底物诱导的不对称还原;(3)使用手性氢化催化剂;(4)酶、整细胞或微生物还原方法。其中(3)与(1)相比,手性试剂用量较少(只需催化量),工业成本较低。 
发明内容
本发明要解决的技术问题是提供一种操作简便、反应条件温和、对映选择性好、环境友好、产率高、成本低的旋光纯富马酸伊布利特的制备方法。 
为解决该技术问题,本发明采用的技术方案如下: 
旋光纯富马酸伊布利特的制备方法,其特征在于以潜手性酮为原料,依次经过下列步骤合成旋光纯伊布利特。 
1、催化还原反应:在惰性气体保持下,-30~45℃温度下,将CBS催化剂,还原剂依次溶于有机溶剂S1中,再向其中滴加潜手性酮的S1溶液,进行不对称催化还原反应0.5-1.5h,经后处理,得到(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺;所述催化剂、还原剂、潜手性酮的摩尔比为1:6~20:10~20。 
2、还原反应:将步骤1中得到的(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺溶于溶剂S2中,在还原剂作用下于0~90℃温度下反应1-12h,经过后处理,得到旋光纯伊布利特;(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺与还原剂的摩尔比为1:1~4。
3、成盐反应:将步骤2中得到的旋光纯伊布利特溶于溶剂无水乙醇中,与富马酸(C4H4O4)在室温下反应,经丙酮重结晶后得到旋光纯富马酸伊布利特,旋光纯伊布利特与富马酸的摩尔比为1:2。 
所述的潜手性酮为N-乙基-N-庚基-4-氧代-4-(4-甲磺酰氨基苯基)丁酰胺;它通过Hester,J.B.;Gibson,J.K.;Cimini,M.G.;Emmert,D.E.;Locker,P.K.;Perricone,S.C.;Skaletzky,L.L.;Sykes,J.K.;West,B.E.N-[(ω-Amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives withclass III antiarrhythmic activity.J.Med.Chem.,1991,34(1):308-315.中记载的方法以甲磺酰苯胺为起始原料,经傅克反应,缩合制得。 
所述的CBS催化剂是一类含N,O配体的环状手性硼化物,由Corey-Bakshi-Shibata等发现的、并以他们命名的CBS催化剂,其结构式为: 
上述步骤1和2中所述的还原剂选自BH3·Me2S、BH3·THF、LiAlH4、DIBAH、NaBH4、LiBH4、NaBH3CN中的一种,其中优选的为LiAlH4或BH3·Me2S或BH3·THF。 
上述步骤1和2中所述的后处理均包括如下步骤: 
首先加入水终止反应,体系静止分层后分离得到有机相和水相,水相用有机溶剂提取,将有机溶剂与有机相合并,用水洗涤后,蒸除溶剂,得到粗产品,粗产品视纯度要求用洗脱剂进行减压蒸馏或重结晶或色谱层析(TLC)分离。所述的色谱层析是硅胶柱色谱层析或薄层色谱层析;所用的洗脱剂为极性溶剂和非极性溶剂混合体系,极性溶剂和非极性溶剂的体积比为1:1~50,极性溶剂和非极性溶剂混合体系为乙酸乙酯-石油醚、乙醚-石油醚、二氯甲烷-石油醚或甲醇-二氯甲烷;所述的有机溶剂为乙酸乙酯。
所述的溶剂S1为醚或卤代烃或芳香烃;所述的醚为C1~C10的单醚、C1~C5的二醚、C1~C8单羟基醚或C5~C10的环醚;所述的C1~C10的单醚,如乙醚,甲基叔丁基醚、丁醚等;C1~C10的二醚,如乙二醇二甲醚、丙二醇二甲醚;C1~C8单羟基醚或C5~C10的环醚,如羟甲基甲醚、四氢呋喃(THF)、四氢吡喃等,其中优选的溶剂为四氢呋喃;所述的卤代烃为C1~C5的单卤代烃或多卤代烃,如二氯甲烷、氯仿,二氯乙烷等,其中优选的溶剂为二氯甲烷等;所述的芳香烃为苯或甲苯,其中优选的溶剂为甲苯。 
所述的溶剂S2为醚;所述的醚为C1~C10的单醚、C1~C10的二醚、C1~C8单羟基醚或C5~C10的环醚;所述的C1~C10的单醚为乙醚、甲基叔丁基醚或丁醚;所述的C1~C10的二醚为乙二醇二甲醚或丙二醇二甲醚;所述的C1~C8单羟基醚或C5~C10的环醚为羟甲基甲醚、四氢呋喃或四氢吡喃。其中优选的溶剂为甲基叔丁基醚、乙醚、丁醚、四氢呋喃或二氧六环,最佳的溶剂为四氢呋喃。 
在本发明制备方法中,采用催化还原法对潜手性酮进行不对称还原,再用LiAlH4对酰胺进行还原,最后与富马酸成盐,合成了旋光纯富马酸伊布利特。实现催化量不对称还原潜手性酮。该合成工艺具有操作简便、反应条件温和、对映选择性好、环境友好、产率高、成本低等优势,具有良好的工业化生产前景。 
附图说明
图1为本发明的工艺流程图。 
具体实施方式
参见图1: 
实施例1
在氮气保护下,室温25℃下,将0.25mmol CBS催化剂溶于5mL无水THF,再加入1.25mL浓度为2mol/L的BH3·Me2S,搅拌10min后,将2.5mmolN-乙基-N-庚基-4-氧代-4-(4-甲磺酰氨基苯基)丁酰胺溶于15mL无水THF,滴加至上述溶液中,室温25℃下搅拌0.5h,TLC跟踪反应。反应结束后,冰浴冷却,依次加入MeOH、水终止反应,用60mL乙酸乙酯萃取水相,乙酸乙酯与有机相合并后依次用水、饱和NaCl洗,无水Na2SO4干燥,减压蒸除溶剂(含乙酸乙酯和THF)。用洗脱剂(甲醇和二氯甲烷的体积比为1:25)进行硅胶柱色谱层析分离得到白色固体:(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺0.8g。(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺:产率80%,m.p.77~78℃,  [ α ] D 20 = - 12.54 , (c1.1,EtOH)[文献值:  [ α ] D 20 = - 13 , (c=0.68,EtOH)]。 
将1.51mmol LiAlH4及无水THF3mL,加至反应瓶中,0℃滴加0.753mmol(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺的无水THF(3mL)溶液。0℃反应3h,TLC跟踪反应。反应结束后,冷却至0℃,滴加乙醇除去未反应的LiAlH4,加入水,用乙酸乙酯萃取,有机相用饱和NaCl洗,无水Na2SO4干燥,减压蒸去溶剂(含乙酸乙酯和THF)。用洗脱剂(甲醇和二氯甲烷的体积比为1:10)进行硅胶柱色谱层析分离得到油状液体:旋光纯伊布利特0.24g。旋光纯伊布利特:产率80%,  [ α ] D 20 = - 15.6 , (c1.2,EtOH)[文献值:  [ α ] D 20 = - 18 , (c=0.352,EtOH)]。 
将0.012mol旋光纯伊布利特溶于25mL无水乙醇,加入0.006mol富马酸的乙醇溶液10mL,室温搅拌0.5h,减压蒸除乙醇,向残留物中加入38mL丙酮,加热回流至溶,冰箱冷冻过夜结晶,过滤,真空干燥,得到白色粉末状固体旋光纯富马酸伊布利特4.35g。旋光纯富马酸伊布利特:产率82%,m.p.117~119℃,  [ α ] D 20 = - 15.54 , (c1.0,EtOH)[文献值:  [ α ] D 20 = - 16 , (c=0.783,EtOH)]。
(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺的核磁谱图为:1H NMR(400MHz,CDCl3)δ:0.89(t,J=5.2Hz,3H),1.15(t,J=7.1Hz,3H),1.29(broad s,8H),1.53(m,2H),2.07(m,2H),2.51(t,J=6.2Hz,2H),2.97(s,3H),3.19-3.43(m,4H),4.79(t,J=5.3Hz,1H),7.20(d,J=8.39Hz,2H),7.32(d,J=8.41Hz,2H).13C NMR(CDCl3)δ:12.9,14.0,22.5,26.8,27.8,28.9,29.6,31.6,34.2,38.8,41.1,42.7,45.9,48.0,72.9,120.9,126.8,136.3,141.7,173.2。 
IR(KBr),σ/cm-1:3258,2930,2857,1615。 
元素分析为:C20H34N2O4S的理论值:C,60.27;H,8.60;N,7.03;S,8.05。实测值:C,60.21;H,8.63;N,7.09;S,8.01。 
(S)-N-[4-[4-(乙基庚基氨基)-1-羟丁基]苯基]甲磺酰胺(旋光纯伊布利特)核磁谱图为:1H NMR(400MHz,CDCl3)δ:0.87(t,J=6.8Hz,3H),1.09(t,J=7.2,3H),1.28(broad s,8H),1.52(m,2H),1.69(broad s,2H),1.93(m,1H),2.41-2.69(m,6H),2.87(s,3H),4.60(t,J=5.6Hz,1H),7.14(d,J=8.40Hz,2H),7.31(d,J=8.43Hz,2H).13C NMR(CDCl3)δ:10.4,14.1,22.6,24.7,25.6,27.6,29.2,31.8,38.8,39.9,46.6,52.8,54.1,73.1,121.1,126.9,135.6,143.2。 
元素分析为:C20H36N2O3S的理论值:C,62.46;H,9.44;N,7.28;S,8.34。实测值:C,62.41;H,9.48;N,7.25;S,8.31。 
(S)-N-[4-[4-(乙基庚基氨基)-1-羟丁基]苯基]甲磺酰胺,(E)-2-丁烯二酸(2:1)(旋光纯富马酸伊布利特)核磁谱图为:1H NMR(400MHz,CDCl3)δ:0.87(t,J=6.7Hz,3H),1.11(t,J=7.2,3H),1.28(broad s,8H),1.53(m,2H),1.69(broad s,4H),2.41-2.69(m,6H),2.87(s,3H),4.60(t,J=5.6Hz,1H),6.47(s,1H),7.14(d,J=8.40Hz,2H),7.31(d,J=8.43Hz,2H)。 
IR(KBr),σ/cm-1:3323,3089,1614,1570。
元素分析为:C22H38N2O5S的理论值:C,59.70;H,8.65;N,6.33;S,7.24。实测值:C,59.68;H,8.63;N,6.36;S,7.25。 
实施例2 
在氮气保护下,将0.125mmol CBS催化剂溶于10mL无水CH2Cl2,再加入2.5mL浓度为1mol/L的BH3·THF,搅拌10min后,冷却至-30℃,将2.5mmol N-乙基-N-庚基-4-氧代-4-(4-甲磺酰氨基苯基)丁酰胺溶于15mL无水CH2Cl2,滴加至上述溶液中,-30℃搅拌1h,TLC跟踪反应。反应结束后,升温至0℃,依次加入MeOH,水终止反应,用60mL CH2Cl2萃取水相,CH2Cl2与有机相合并后依次用水,饱和NaCl洗,无水Na2SO4干燥,减压蒸除溶剂(CH2Cl2)。用洗脱剂(甲醇和二氯甲烷的体积比为1:25)进行硅胶柱层析分离得到白色固体:(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺0.65g。(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺:白色固体,产率65%,m.p.77~78℃。  [ α ] D 20 = - 12.10 , (c1.1,EtOH)[文献值:  [ α ] D 20 = - 13 , (c=0.68,EtOH)]。 
将3.012mmol LiAlH4及3mL无水THF,加至反应瓶中,0℃滴加0.753mmol(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺的无水THF(3mL)溶液,加热至45℃反应3h,TLC跟踪反应。反应结束后,冷却至0℃,滴加乙醇除去未反应的LiAlH4,加入水,用乙酸乙酯萃取,有机相用饱和NaCl洗,无水Na2SO4干燥,减压蒸去溶剂(含乙酸乙酯和THF)。用洗脱剂(甲醇和二氯甲烷的体积比为1:10)进行硅胶柱层析分离得到油状液体:旋光纯伊布利特0.24g。旋光纯伊布利特:产率80%,  [ α ] D 20 = - 15.6 , (c1.2,EtOH)[文献值:  [ α ] D 20 = - 18 , (c=0.352,EtOH)]。 
将0.012mol旋光纯伊布利特溶于25mL无水乙醇,加入0.006mol富马酸的乙醇溶液10mL,室温搅拌0.5h。减压蒸除乙醇,向残留物中加入38mL 丙酮,加热回流至溶,冰箱冷冻过夜结晶。过滤,真空干燥,得白色粉末状固体:旋光纯富马酸伊布利特4.35g。旋光纯富马酸伊布利特:产率82%,m.p.117~119℃,  [ α ] D 20 = - 15.54 , (c 1.0,EtOH)[文献值:  [ α ] D 20 = - 16 , (c=0.783,EtOH)]。 
(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺核磁谱图为: 1H NMR(400MHz,CDCl3)δ:0.89(t,J=5.2Hz,3H),1.15(t,J=7.1Hz,3H),1.29(broad s,8H),1.53(m,2H),2.07(m,2H),2.51(t,J=6.2Hz,2H),2.97(s,3H),3.19-3.43(m,4H),4.79(t,J=5.3Hz,1H),7.20(d,J=8.39Hz,2H),7.32(d,J=8.41Hz,2H).13C NMR(CDCl3)δ:12.9,14.0,22.5,26.8,27.8,28.9,29.6,31.6,34.2,38.8,41.1,42.7,45.9,48.0,72.9,120.9,126.8,136.3,141.7,173.2。 
IR(KBr),σ/cm-1:3258,2930,2857,1615。 
元素分析为:C20H34N2O4S的理论值:C,60.27;H,8.60;N,7.03;S,8.05.实测值:C,60.21;H,8.63;N,7.09;S,8.01。 
(S)-N-[4-[4-(乙基庚基氨基)-1-羟丁基]苯基]甲磺酰胺(旋光纯伊布利特)核磁谱图为:1H NMR(400MHz,CDCl3)δ:0.87(t,J=6.8Hz,3H),1.09(t,J=7.2,3H),1.28(broad s,8H),1.52(m,2H),1.69(broad s,2H),1.93(m,1H),2.41-2.69(m,6H),2.87(s,3H),4.60(t,J=5.6Hz,1H),7.14(d,J=8.40Hz,2H),7.31(d,J=8.43Hz,2H).13C NMR(CDCl3)δ:10.4,14.1,22.6,24.7,25.6,27.6,29.2,31.8,38.8,39.9,46.6,52.8,54.1,73.1,121.1,126.9,135.6,143.2。 
元素分析为:C20H36N2O3S的理论值:C,62.46;H,9.44;N,7.28;S,8.34。实测值:C,62.41;H,9.48;N,7.25;S,8.31。 
(S)-N-[4-[4-(乙基庚基氨基)-1-羟丁基]苯基]甲磺酰胺,(E)-2-丁烯二酸(2:1)(旋光纯富马酸伊布利特)核磁谱图为:1H NMR(400MHz,CDCl3) δ:0.87(t,J=6.7Hz,3H),1.11(t,J=7.2,3H),1.28(broad s,8H),1.53(m,2H),1.69(broad s,4H),2.41-2.69(m,6H),2.87(s,3H),4.60(t,J=5.6Hz,1H),6.47(s,1H),7.14(d,J=8.40Hz,2H),7.31(d,J=8.43Hz,2H). 
IR(KBr),σ/cm-1:3323,3089,1614,1570。 
元素分析为:C22H38N2O5S的理论值:C,59.70;H,8.65;N,6.33;S,7.24。实测值:C,59.68;H,8.63;N,6.36;S,7.25。 
实施例3 
在氮气保护下,将0.25mmol CBS催化剂溶于10mL无水PhCH3,再加入0.75mL浓度为2mol/LBH3·Me2S,搅拌10min后,加热至45℃,将3.75mmolN-乙基-N-庚基-4-氧代-4-(4-甲磺酰氨基苯基)丁酰胺溶解于15mL无水PhCH3,滴加至反应瓶中,45℃搅拌1.5h,,TLC跟踪反应。反应结束后,依次加入MeOH,水终止反应,60mL乙酸乙酯萃取萃取,乙酸乙酯与有机相合并后依次用水,饱和NaCl洗,无水Na2SO4干燥,减压蒸除溶剂(含乙酸乙酯和PhCH3)。用洗脱剂(甲醇和二氯甲烷的体积比为1:25)进行硅胶柱层析分离得到白色固体(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺0.675g。(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺:白色固体,产率45%,  [ α ] D 20 = - 11.50 , (c1.1,EtOH)[文献值:  [ α ] D 20 = - 13 , (c=0.68,EtOH)]。 
将0.753mmol LiAlH4及3mL无水THF,加至反应瓶中,0℃滴加0.753mmol(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺的无水THF(3mL)溶液,加热至90℃反应3h,TLC跟踪反应。反应结束后,冷却至0℃,滴加乙醇除去未反应的LiAlH4,加入水,用乙酸乙酯萃取,有机相用饱和NaCl洗,无水Na2SO4干燥,减压蒸去溶剂(含乙酸乙酯和THF)。用洗脱剂(甲醇和二氯甲烷的体积比为1:10)进行硅胶柱层析分离得到 油状液体:旋光纯伊布利特0.24g。旋光纯伊布利特:产率80%,  [ α ] D 20 = - 15.6 , (c 1.2,EtOH)[文献值:  [ α ] D 20 = - 18 , (c=0.352,EtOH)]。 
将0.012mol旋光纯伊布利特溶于25mL无水乙醇,加入0.006mol富马酸的乙醇溶液10mL,室温搅拌0.5h。减压蒸除乙醇,向残留物中加入38mL丙酮,加热回流至溶,冰箱冷冻过夜结晶。过滤,真空干燥,得白色粉末状固体旋光纯富马酸伊布利特4.35g。旋光纯富马酸伊布利特:产率82%,m.p.117~119℃,  [ α ] D 20 = - 15.54 , (c 1.0,EtOH)[文献值:  [ α ] D 20 = - 16 , (c=0.783,EtOH)]。 
(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺核磁谱图为: 1H NMR(400MHz,CDCl3)δ:0.89(t,J=5.2Hz,3H),1.15(t,J=7.1Hz,3H),1.29(broad s,8H),1.53(m,2H),2.07(m,2H),2.51(t,J=6.2Hz,2H),2.97(s,3H),3.19-3.43(m,4H),4.79(t,J=5.3Hz,1H),7.20(d,J=8.39Hz,2H),7.32(d,J=8.41Hz,2H).13C NMR(CDCl3)δ:12.9,14.0,22.5,26.8,27.8,28.9,29.6,31.6,34.2,38.8,41.1,42.7,45.9,48.0,72.9,120.9,126.8,136.3,141.7,173.2。 
IR(KBr),σ/cm-1:3258,2930,2857,1615。 
元素分析为:C20H34N2O4S的理论值:C,60.27;H,8.60;N,7.03;S,8.05。实测值:C,60.21;H,8.63;N,7.09;S,8.01。 
(S)-N-[4-[4-(乙基庚基氨基)-1-羟丁基]苯基]甲磺酰胺(旋光纯伊布利特)核磁谱图为:1H NMR(400MHz,CDCl3)δ:0.87(t,J=6.8Hz,3H),1.09(t,J=7.2,3H),1.28(broad s,8H),1.52(m,2H),1.69(broad s,2H),1.93(m,1H),2.41-2.69(m,6H),2.87(s,3H),4.60(t,J=5.6Hz,1H),7.14(d,J=8.40Hz,2H),7.31(d,J=8.43Hz,2H).13C NMR(CDCl3)δ:10.4,14.1,22.6,24.7,25.6,27.6,29.2,31.8,38.8,39.9,46.6,52.8,54.1,73.1,121.1,126.9,135.6,143.2。
元素分析为:C20H36N2O3S的理论值:C,62.46;H,9.44;N,7.28;S,8.34.实测值:C,62.41;H,9.48;N,7.25;S,8.31。 
(S)-N-[4-[4-(乙基庚基氨基)-1-羟丁基]苯基]甲磺酰胺,(E)-2-丁烯二酸(2:1)(旋光纯富马酸伊布利特)核磁谱图为:1H NMR(400MHz,CDCl3)δ:0.87(t,J=6.7Hz,3H),1.11(t,J=7.2,3H),1.28(broad s,8H),1.53(m,2H),1.69(broad s,4H),2.41-2.69(m,6H),2.87(s,3H),4.60(t,J=5.6Hz,1H),6.47(s,1H),7.14(d,J=8.40Hz,2H),7.31(d,J=8.43Hz,2H)。 
IR(KBr),σ/cm-1:3323,3089,1614,1570。 
元素分析为:C22H38N2O5S的理论值:C,59.770;H,8.65;N,6.33;S,7.24。实测值:C,59.68;H,8.63;N,6.36;S,7.25。

Claims (3)

1.旋光纯(S)-富马酸伊布利特的制备方法,其特征在于:以N-乙基-N-庚基-4-氧代-4-(4-甲磺酰氨基苯基)丁酰胺为原料,依次经过下列步骤合成:
A、催化还原反应:在氮气保护下,-30~45℃温度下,将CBS催化剂,还原剂:BH3·Me2S或BH3·THF,依次溶于有机溶剂S1中,再向其中滴加N-乙基-N-庚基-4-氧代-4-(4-甲磺酰氨基苯基)丁酰胺的S1溶液,进行不对称催化还原反应0.5-1.5h,经后处理得到(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺;所述催化剂、还原剂、N-乙基-N-庚基-4-氧代-4-(4-甲磺酰氨基苯基)丁酰胺的摩尔比为1∶6~20∶10~20;所述的有机溶剂S1为无水THF或无水CH2Cl2或无水PhCH3
B、还原反应:将步骤A中得到的(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺溶于无水四氢呋喃中,在还原剂LiAlH4作用下于0~90℃温度下反应1-12h,经过后处理得到旋光纯(S)-伊布利特;(S)-N-乙基-N-庚基-4-羟基-4-(4-(甲磺酰胺)苯基)丁酰胺与还原剂的摩尔比为1∶1~4;
C、成盐反应:将步骤B中得到的旋光纯(S)-伊布利特溶于无水乙醇中,与富马酸在室温下反应,经丙酮重结晶后得到旋光纯(S)-富马酸伊布利特,旋光纯(S)-伊布利特与富马酸的摩尔比为1∶2。
2.根据权利要求1所述的制备方法,其特征在于:步骤A、B中所述的后处理均包括以下步骤:
首先加入水终止反应,体系静止分层后分离得到有机相和水相,水相用乙酸乙酯提取,将乙酸乙酯与有机相合并,用水洗涤后,蒸除溶剂,得到粗产品,粗产品用洗脱剂进行硅胶柱色谱层析分离。
3.根据权利要求2所述的制备方法,其特征在于:所述的洗脱剂为甲醇和二氯甲烷的混和物,甲醇与二氯甲烷的体积比为1∶10~25。
CN2008101221881A 2008-11-10 2008-11-10 旋光纯富马酸伊布利特的制备方法 Expired - Fee Related CN101412687B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2008101221881A CN101412687B (zh) 2008-11-10 2008-11-10 旋光纯富马酸伊布利特的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2008101221881A CN101412687B (zh) 2008-11-10 2008-11-10 旋光纯富马酸伊布利特的制备方法

Publications (2)

Publication Number Publication Date
CN101412687A CN101412687A (zh) 2009-04-22
CN101412687B true CN101412687B (zh) 2012-01-11

Family

ID=40593456

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008101221881A Expired - Fee Related CN101412687B (zh) 2008-11-10 2008-11-10 旋光纯富马酸伊布利特的制备方法

Country Status (1)

Country Link
CN (1) CN101412687B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103936564B (zh) * 2014-03-28 2016-05-11 济南康和医药科技有限公司 泊沙康唑中间体(2s,3r)-2-苄氧基-3-戊醇的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172475A (zh) * 1995-01-10 1998-02-04 法玛西雅厄普约翰美国公司 抗心律失常的甲磺酰胺(s)-对映体
CN1733714A (zh) * 2005-07-12 2006-02-15 浙江九旭药业有限公司 富马酸伊布利特的合成方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172475A (zh) * 1995-01-10 1998-02-04 法玛西雅厄普约翰美国公司 抗心律失常的甲磺酰胺(s)-对映体
CN1733714A (zh) * 2005-07-12 2006-02-15 浙江九旭药业有限公司 富马酸伊布利特的合成方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sam C. Perricone et al.Synthesis of (R)-N-[4-[4-(Dibutylamino)-1-hydroxybutyl]phenyl]methanesulfonamide,(E)-2-Butenedioate(2:1)Salt(Artilide Fumarate)and the Enantiomers of N-[4-[4-(Ethylheptylamino)-1-hydroxybutyl]phenyl]methanesulfonamide,(E)-2-Butenedioate(2:1)Salt(Ibutilide).《Tetrahedron: Asymmetry》.1996,第7卷(第3期),677-690. *

Also Published As

Publication number Publication date
CN101412687A (zh) 2009-04-22

Similar Documents

Publication Publication Date Title
Gao et al. Asymmetric synthesis of both enantiomers of tomoxetine and fluoxetine. Selective reduction of 2, 3-epoxycinnamyl alcohol with Red-Al
Mimura et al. Trifluoroacetaldehyde: a useful industrial bulk material for the synthesis of trifluoromethylated amino compounds
Harmata et al. Congeners of Troeger's base as chiral ligands
Szakonyi et al. Enantioselective addition of diethylzinc to aldehydes catalyzed by γ-amino alcohols derived from (+)-and (−)-α-pinene
Beak et al. Displacements at the nitrogen of lithioalkoxylamides by organometallic reagents
Imamoto et al. Improved synthetic routes to methylene-bridged P-chiral diphosphine ligands via secondary phosphine–boranes
CN105859622B (zh) 钯催化不对称氢化合成手性氟代吡唑啉酮类衍生物的方法
Lu et al. The Ru-catalyzed enantioselective preparation of chiral halohydrins and their application in the synthesis of (R)-clorprenaline and (S)-sotalol
Zhao et al. Asymmetric Mannich‐Type Reaction of a Chiral N‐(tert‐Butylsulfinyl) Ketimine with Imines: Application to the Synthesis of Chiral 1, 3‐Diamines
CN101412687B (zh) 旋光纯富马酸伊布利特的制备方法
Zhou et al. Chiral 1, 2, 3, 4-tetrahydroquinolinyl-oxazoline ligands for Ru-catalyzed asymmetric transfer hydrogenation of ketones
CN107032972B (zh) 具有2’-羟基查尔酮结构Diels-Alder产物的制备方法
CN110272403B (zh) 一种合成含苯并二氢呋喃环和三氟甲基的氨基甲酸酯的方法
Tlahuext et al. N-alkyloxazaborolidines derived from ephedrines.
Iuliano et al. Optically active N-1-phenylethyl derivatives of (1R)-2-amino-1-phenylethanol as chiral auxiliaries in the enantioselective addition of diethylzinc to arylaldehydes
CN114539077A (zh) 一种盐酸左沙丁胺醇的合成方法
CN113277963B (zh) 一种胺类化合物及其制备方法与应用
CN102180886B (zh) 加兰他敏不对称催化合成方法
Gibson et al. Application of chiral lithium amide base chemistry to the synthesis of planar chiral (arene) tricarbonylchromium (0) complexes
Sun et al. Synthesis of new Schiff base-camphorsulfonyl amide ligands and in situ screening in the asymmetric additions of organozinc reagents to aldehydes
JP3976357B2 (ja) 光学活性アルコールの製造方法
CN109251227A (zh) 一类包含二茂铁骨架和刚性螺环结构的手性化合物及合成与应用
Yamazaki et al. Regio-as well as stereoselective epoxide ring opening reactions using 3, 3, 3-trifluoroprop-1‑yne
CN110903177A (zh) 一种制备左旋麝香酮的方法
Higashijima et al. cis-1-Amino-1, 2, 3, 4-tetrahydro-2-naphthalenol: resolution and application to the catalytic enantioselective reduction of ketones

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120111

Termination date: 20131110